Benign Prostatic Hyperplasia Treatment Market is growing at a CAGR of 5.3% from 2024 to 2030 by Exactitude Consultancy

The Exactitude Consultancy Benign Prostatic Hyperplasia Treatment Market Report – Size, Trends, and Forecast 2024-2030

LUTON, BEDFORDSHIRE, UNITED KINGDOM, August 19, 2024 /EINPresswire.com/ -- An insightful market analysis report focusing on the 𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 has just been released by Exactitude Consultancy, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Benign Prostatic Hyperplasia Treatment market and its sub segments, providing revenue forecasts and strategic insights that can drive business success in the coming years in Life Sciences Industry.  The research spotlights on the latest market insights, current situation analysis with upcoming trends, and breakdown of the products and services. It covers information on profit models, competition spectrum, and associated vendor strategies illustrated by major players and market participants. The report comprises an in-depth analysis and comprehensive analysis about the future trends as well as developments of the market. Additionally, insights regarding possible opportunities present in the global Benign Prostatic Hyperplasia Treatment market would help stakeholders in implementing strategic business plans. Various factors that may drive the growth of the global market in the current scenario, as well as coming years, have been discussed in detail.

𝐓𝐡𝐞 𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 𝟓.𝟖𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐭𝐨 𝐔𝐒𝐃 𝟗.𝟕𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟑% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.

𝐆𝐞𝐭 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭:

https://exactitudeconsultancy.com/reports/6559/benign-prostatic-hyperplasia-treatment-market/#request-a-sample

In addition to answering these critical questions, the report offers a forward-looking perspective, providing insights into the future trajectory of the Benign Prostatic Hyperplasia Treatment market. It equips decision-makers with the knowledge needed to navigate the market’s evolution during the forecasted period effectively.

𝐓𝐡𝐞 𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐩𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭:

Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭:

In April 2022, Teleflex announced the launch of the UroLift System in Japan for the treatment of benign prostatic hyperplasia (BPH). The FDA had cleared the usage of UroLift System for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

In September 2018, Boston Scientific Corporation acquired Augmenix, the developer of SpaceOAR intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy

This Benign Prostatic Hyperplasia Treatment research report sheds light on the major market players who are thriving in the market. Track business strategy, financial status and upcoming products.

𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟐𝟗, (𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧)

Drug Class

Minimally Invasive Surgeries

Laser Therapy

𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟐𝟗, (𝐔𝐒𝐃 𝐌𝐢𝐥𝐥𝐢𝐨𝐧)

Hospitals

Ambulatory Surgical Centres

Specialty Clinics

This report caters to a wide audience, from industry experts seeking insights into the dynamic Benign Prostatic Hyperplasia Treatment market to newcomers looking for guidance. Customization options are available to ensure the report’s relevance to your specific needs.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

𝐃𝐫𝐢𝐯𝐞𝐫: 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐛𝐞𝐧𝐢𝐠𝐧 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐡𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚

Benign prostatic hyperplasia refers to the nonmalignant growth of prostate tissue and is a frequent cause of lower urinary tract symptoms among men. BPH is considered a normal part of male aging and is hormonally dependent on testosterone and dihydrotestosterone (DHT) production. Approximately 50% of men demonstrate histopathologic benign prostatic hyperplasia by age 60 and 90% by age 85. Approximately 30 million men worldwide and 14 million men in the US are said to have benign prostatic hyperplasia symptoms.

Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 revealed that nearly 7,600,000 patients were diagnosed with benign prostatic hyperplasia in 2010, which increased by 1.2 million in 2017. This represents an annual increase of about 7% and a total increase of 58% from 2010.

𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲: 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞

The market for treatments for benign prostatic hyperplasia presents significant growth opportunities for generic drug manufacturers. Generic versions are now available since the majority of drugs used to treat benign prostatic hyperplasia—including Avodart, Cialis, and Jalyn—have had their patents revoked. In addition, there is a robust product pipeline in the market for treatments for benign prostatic hyperplasia due to increased demand for more efficacious treatment options.

𝐓𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐬 𝐦𝐚𝐢𝐧𝐥𝐲 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐢𝐧𝐭𝐨 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐤𝐞𝐲 𝐫𝐞𝐠𝐢𝐨𝐧𝐬, 𝐰𝐢𝐭𝐡 𝐬𝐚𝐥𝐞𝐬, 𝐫𝐞𝐯𝐞𝐧𝐮𝐞, 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐡𝐚𝐫𝐞, 𝐚𝐧𝐝 𝐠𝐫𝐨𝐰𝐭𝐡 𝐫𝐚𝐭𝐞 𝐢𝐧 𝐭𝐡𝐞𝐬𝐞 𝐫𝐞𝐠𝐢𝐨𝐧𝐬, 𝐜𝐨𝐯𝐞𝐫𝐢𝐧𝐠:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

𝐊𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭:

https://exactitudeconsultancy.com/reports/6559/benign-prostatic-hyperplasia-treatment-market/

𝐓𝐡𝐞 𝐬𝐭𝐮𝐝𝐲 𝐚𝐥𝐬𝐨 𝐚𝐧𝐚𝐥𝐲𝐳𝐞𝐬 𝐚𝐧𝐝 𝐬𝐡𝐞𝐝𝐬 𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐤𝐞𝐲 𝐚𝐬𝐩𝐞𝐜𝐭𝐬 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐭𝐨 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭’𝐬 𝐠𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐠𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐞𝐬:

Regions witnessing a rise in investments in supply chain networks.

Countries that have benefited from recent import and export policies.

Regions experiencing a decline in consumer demand due to economic and political upheavals.

Benign Prostatic Hyperplasia Treatment Markets expected to emerge in specific geographies.

Regions likely to lose market share due to pricing pressures.

Leading players expected to expand their footprints in the near future.

Sustainability trends impacting the logistics and supply chain dynamics in the Benign Prostatic Hyperplasia Treatment

Demographic and economic environments creating new demand in developing economies.

Changing government regulations and their impact on business strategies and practices.

𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:

What is the expected market size and growth rate during the forecast period?

What are the key factors propelling the Benign Prostatic Hyperplasia Treatment market?

What risks and challenges lie ahead in the market?

Who are the prominent players in the Benign Prostatic Hyperplasia Treatment market?

What trends are influencing market shares?

What are the primary findings from Porter’s five forces model?

What global expansion opportunities are available for the Benign Prostatic Hyperplasia Treatment market?

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐩𝐮𝐫𝐩𝐨𝐬𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭?

A thorough review of the Benign Prostatic Hyperplasia Treatment Market, including regional markets.

Comprehensive coverage of all segments of the Market to assess trends, developments and market size forecasts till 2024-2030.

A thorough examination of deals involved in the Market including product portfolio, revenue, SWOT analysis and recent company advancements are examined in the company profile.

The growth matrix analyzes the product categories and geographic regions in which market companies should focus their efforts to invest, consolidate, expand and/or diversify.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐋𝐢𝐧𝐤𝐬:

https://exactitudeconsultancy.com/ko/reports/6559/benign-prostatic-hyperplasia-treatment-market/

https://exactitudeconsultancy.com/zh-CN/reports/6559/benign-prostatic-hyperplasia-treatment-market/

https://exactitudeconsultancy.com/ja/reports/6559/benign-prostatic-hyperplasia-treatment-market/

https://exactitudeconsultancy.com/fr/reports/6559/benign-prostatic-hyperplasia-treatment-market/

https://exactitudeconsultancy.com/de/reports/6559/benign-prostatic-hyperplasia-treatment-market/

𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭:

20% free customization.

Five Countries can be added as per your choice.

Five Companies can add as per your choice.

Free customization up to 40 hours.

Post-sales support for 1 year from the date of delivery.

𝐆𝐞𝐭 𝐌𝐨𝐫𝐞:https://exactitudeconsultancy.com/primary-research/

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

𝐄𝐱𝐚𝐜𝐭𝐢𝐭𝐮𝐝𝐞 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐚𝐧𝐜𝐲 is a Market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you. So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

𝐂𝐡𝐞𝐜𝐤 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐮𝐩𝐝𝐚𝐭𝐞𝐬:https://bulletin.exactitudeconsultancy.com

Irfan T
Exactitude Consultancy
+1 704-266-3234
email us here
Visit us on social media:
X
LinkedIn